David A. Eberhard
University of North Carolina at Chapel Hill(US)
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research, Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib(2005)1,482 cited
- → Diverse somatic mutation patterns and pathway alterations in human cancers(2010)1,025 cited
- → Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer(2005)536 cited
- → Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients(2005)490 cited
- → Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib(2005)465 cited
- → Histopathology of arteriovenous malformations after gamma knife radiosurgery(1997)343 cited